Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
…, A Beny, HMW Van Laarhoven, BA DiCarlo… - The Lancet …, 2019 - thelancet.com
Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
…, L Zehngebot, H Allen, L Bosserman, B DiCarlo… - Nature …, 2020 - nature.com
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor
J Zhang, NP McAndrew, X Wang, Y Du, B DiCarlo… - Breast Cancer …, 2023 - Springer
Background Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of
developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor …
developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor …
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain …
…, E Hu, J Berkowitz, A Mani, B DiCarlo… - … in medical oncology, 2018 - journals.sagepub.com
Background: Improving outcomes for patients with human epidermal growth factor 2-positive
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …
Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
…, LM Spring, S Applebaum, S Dakhil, B DiCarlo… - Cancer Research, 2023 - AACR
Background: Although patients (pts) with hormone receptor-positive (HR+)/HER2-negative
breast cancer (BC) frequently experience disease response to neoadjuvant therapy, fewer …
breast cancer (BC) frequently experience disease response to neoadjuvant therapy, fewer …
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
…, S Applebaum, E Chamberlain, SR Dakhil, BA DiCarlo… - 2022 - ascopubs.org
TPS623 Background: Although patients with hormone receptor-positive (HR+)/HER2-negative
breast cancer (BC) frequently experience disease response to neoadjuvant therapy, …
breast cancer (BC) frequently experience disease response to neoadjuvant therapy, …
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for …
ZA Wainberg, HP Soares, R Patel, B DiCarlo… - Cancer chemotherapy …, 2015 - Springer
Purpose Our study was designed to evaluate the efficacy and safety of everolimus in patients
with pre-treated metastatic gastric and esophagus cancers in a US-based population …
with pre-treated metastatic gastric and esophagus cancers in a US-based population …
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer
…, WE Lawler, B Telivala, F Braiteh, BA DiCarlo… - Lung Cancer, 2019 - Elsevier
Background Luminespib (AUY922) is a second-generation heat shock protein 90 (HSP90)
inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC). Since luminespib …
inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC). Since luminespib …
A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary …
EP Hamilton, MJ Birrer, BA DiCarlo, S Gaillard… - 2015 - ascopubs.org
5571 Background: Treating patients (pts) with relapsed ovarian cancer remains challenging.
Birinapant is a bivalent SMAC mimetic in clinical development for solid and hematological …
Birinapant is a bivalent SMAC mimetic in clinical development for solid and hematological …
An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
…, M Rettig, F Khan, DR Greenwald, B DiCarlo… - 2014 - ascopubs.org
169 Background: IRX4204 is a potent, selective, oral small compound agonist of retinoid X
receptor (RXR) nuclear receptor pathways. In preclinical studies IRX4204 synergizes with …
receptor (RXR) nuclear receptor pathways. In preclinical studies IRX4204 synergizes with …